PTPRC and breast carcinoma: Consistent with our earlier findings [3], NKG2D+ cancer cells were present in all 12 breast cancer specimens, ranging between 0.5 and 27.8% (mean 9.7 +/− 9.1%) of total CD45–EpCAMhigh cells (Table S1).